Advagene Biopharma Co (ROCO:6709) Total Equity : NT$85.13 Mil (As of Jun. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Advagene Biopharma Co Total Equity?

Advagene Biopharma Co's total equity for the quarter that ended in Jun. 2023 was NT$85.13 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Advagene Biopharma Co Total Equity Historical Data

The historical data trend for Advagene Biopharma Co's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Advagene Biopharma Co Total Equity Chart

Advagene Biopharma Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Equity

Get a 7-Day Free Trial

271.37

299.33

249.57

131.76

139.96

Advagene Biopharma Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Total Equity	Get a 7-Day Free Trial										249.57	194.16	131.76	85.13	139.96

Advagene Biopharma Co Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Advagene Biopharma Co's Total Equity for the fiscal year that ended in Dec. 2023 is calculated as

Total Equity	=	Total Assets(Q: Dec. 2023 )	-	Total Liabilities(Q: Dec. 2023 )
	=	147.934	-	7.972
	=	139.96

Advagene Biopharma Co's Total Equity for the quarter that ended in Jun. 2023 is calculated as

Total Equity	=	Total Assets(Q: Jun. 2023 )	-	Total Liabilities(Q: Jun. 2023 )
	=	93.904	-	8.771
	=	85.13

Advagene Biopharma Co Total Equity Related Terms

Thank you for viewing the detailed overview of Advagene Biopharma Co's Total Equity provided by GuruFocus.com. Please click on the following links to see related term pages.

Advagene Biopharma Co (ROCO:6709) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Advagene Biopharma Co Ltd (ROCO:6709) » Definitions » Total Equity

Comparable Companies

Traded in Other Exchanges

N/A

Address

Sector 1, Neihu Road, 6 Floor, No.308, Neihu District, Taipei, TWN, 114

Website

http://www.advagene.com.tw

Advagene Biopharma Co Ltd is a Taiwan based immune-modulatory platform-based drug developer. The company has completed technology transfer with DCB for detoxified LT Adjuvant Technology Platform. Its product development includes nasal spray influenza vaccine (LT-Flu), allergy vaccines (LT-Allergy), and other vaccines.

Advagene Biopharma Co (ROCO:6709) Headlines

No Headlines